Synvolux Therapeutics

RSS Subscribe

Synvolux Therapeutics B.V. is a privately held biotech company dedicated to the development, production and commercialisation of new therapies using its SAINT technology: an unique, safe and highly efficacious delivery technology for macromolecules (DNA, RNA, proteins and others). Synvolux sells its products for R&D use.

Synvolux Therapeutics uses its SAINT technology for the delivery of drugs based on synthetic, non-toxic chemical compounds. We develop novel products with designed features to meet the needs of our drug development partners and our own programs. Synvolux' compounds promise to improve the potential of DNA mediated therapy, circumventing the dangers of viral delivery and the inefficiency of other approaches.

Contact:

L.J. Zielstraweg 1
9713 GX
Gronigen
The Netherlands

Tel: +31 50 311 8115
Fax: +31 50 311 8995

Website: www.synvolux.nl

Articles by Synvolux Therapeutics

Cell Transfection Reagents


In Vitro Gene Silencing


Intracellular Protein Delivery


Protein Delivery Reagents

  • Protein transfection reagent SAINT PhD »
    SAINT-PhD protein delivery reagent is based on a synthetic amphiphilic (non-liposomal) delivery system combined with DOPE (Dioleoyl-phosphatidylethanolamine).


Synthetic Delivery Systems


Transfection Reagent

  • siRNA transfection reagent SAINT RED »
    SAINT-RED provides highly efficient siRNA transfection over a range of siRNA concentrations from low to high, allowing researchers to choose the siRNA concentration they wish to use.

RSS